icon-folder.gif   Conference Reports for NATAP  
 
  65th Annual Meeting of the
American Association for the
Study of Liver Diseases
Boston, MA Nov 7-11 2014
Back grey_arrow_rt.gif
 
 
 
SVR12 Rate of 98.6% in 992 HCV Genotype 1b-Infected Patients Treated With ABT-450/r/Ombitasvir and Dasabuvir With or Without Ribavirin
 
 
  Reported by Jules Levin
AASLD 2014 Boston Nov 7-11
 
Massimo G Colombo1, Ola Weiland2, Daniel E Cohen3, Jean-Francois DuFour4, Hendrik Reynaert5, Moisés Diago6, Erica Villa7, Adrian Streinu-Cercel8, Wangang Xie3, Jeff rey V Enejosa3, Eoin Coakley3,
Roger Trinh3, Thomas Podsadecki3
1Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Universita degli Studi di Milano, Milan, Italy; 2Karolinska University Hospital Huddinge, Karolinska Institutet, Stockholm, Sweden; 3AbbVie Inc., North Chicago, Illinois, United States; 4Inselspital Bern, Bern, Switzerland;
5Universitair Ziekenhuis Brussels, Brussels, Belgium; 6Hospital Quiron de Valencia, Valencia, Spain; 7AOU Policlinico di Modena, Modena, Italy; 8Carol Davila University of Medicine and Pharmacy, National Institute for Infectious Diseases "Prof. Dr. Matei Bals," Bucharest, Romania

AASLD1.gif

AASLD2.gif

AASLD3.gif

AASLD4.gif

AASLD5.gif

AASLD6.gif

AASLD7.gif

AASLD8.gif

AASLD9.gif

AASLD10.gif